One of the problems in migraine treatment has always been the need to use multiple drugs to obtain a satisfactory clinical result.
All this often went to the detriment of safety, more preventive drugs meant greater risk of side effects and therefore of suspension of the therapy itself.
In addition, the efficacy of the combined therapy of several drugs could be compromised due to the possible metabolic interactions between the drugs.
All this often favored the natural chronicization of migraine and with a consequent uncontrolled use of analgesics.
Recent studies have now pointed out that the current availability of highly effective drugs for migraine can quickly decronic it with a very modest index of possible adverse effects.
These drugs, the monoclonal antibodies to Calcitonin-Gene-Related-Peptide or its receptor are now available in all Regions and are dispensed through a Treatment Plan that can be drawn up by approximately 210 centers authorized nationally for the treatment of high migraine. frequency or chronic in favor of patients who have not responded adequately to previous therapies.
The same therapeutic paradigm but for the chronic form of migraine has already been available and used for some time, and is based on the use of botulinum toxin.
A recent analysis of the safety and efficacy advantages of monotherapy compared to the combination of multiple therapies for migraine appeared today in the prestigious scientific journal Expert Opinion on Drug Safety by the researchers of the Paolo Martelletti group of the Sapienza University at the Hospital. Sant'Andrea of Rome.
The future of migraine foresees the use of further pharmacological classes, the gepants and the ditans, which used individually will allow to obtain a control of the frequency and intensity of migraine and its painful and strongly disabling painful crises.